Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zai Lab In-licenses NSCLC Candidate from Turning Point in $176 Million Deal

publication date: Jul 7, 2020

Zai Lab, a Shanghai biopharma, signed a $176 million deal to acquire Greater China rights to a novel cancer drug developed by San Diego's Turning Point Therapeutics. Zai will pay $25 million upfront and up to $151 million in milestones. Currently ready to start Phase II trials, repotrectinib is a next-gen TKI that targets ROS1 and TRK A/B/C. ROS1 rearrangement is thought to be an oncogenic driver in 2%-3% of China patients with advanced NSCLC. Zai will add China sites to the Phase II global trial of repotrectinib. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: TPTX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021